IKT-904

N/A

Report date: 2026/03/19 16:53:34

Base Information

Drug NameIKT-904
Drug Alias Nameanti-CD3/anti-HER2 bispecific T-cell engager (Icell Kealex)HER2-TEA-VVIKT-904
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Oncolytic virusBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsImmunostimulantsReceptor protein-tyrosine kinase erbB-2 modulators +[4] 
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIcell Kealex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A